Argenx Operating Margin from 2010 to 2024
| ARGX Stock | USD 614.59 7.43 1.22% |
Check Argenx NV financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Argenx NV's main balance sheet or income statement drivers, such as Depreciation And Amortization of 117.1 M, Interest Expense of 858.8 K or Selling General Administrative of 532.8 M, as well as many indicators such as Price To Sales Ratio of 16.85, Dividend Yield of 0.0 or PTB Ratio of 7.68. Argenx financial statements analysis is a perfect complement when working with Argenx NV Valuation or Volatility modules.
Argenx | Operating Margin |
Latest Argenx NV's Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of argenx NV ADR over the last few years. It is Argenx NV's Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Argenx NV's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 0.03 % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
Argenx Operating Margin Regression Statistics
| Arithmetic Mean | (2.87) | |
| Coefficient Of Variation | (98.35) | |
| Mean Deviation | 1.80 | |
| Median | (2.33) | |
| Standard Deviation | 2.83 | |
| Sample Variance | 7.99 | |
| Range | 11.1227 | |
| R-Value | 0.21 | |
| Mean Square Error | 8.23 | |
| R-Squared | 0.04 | |
| Significance | 0.46 | |
| Slope | 0.13 | |
| Total Sum of Squares | 111.84 |
Argenx Operating Margin History
About Argenx NV Financial Statements
Argenx NV investors use historical fundamental indicators, such as Argenx NV's Operating Margin, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Argenx NV. Please read more on our technical analysis and fundamental analysis pages.
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Ltd, Universit Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands. Argenx Se is traded on NASDAQ Exchange in the United States.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Argenx Stock Analysis
When running Argenx NV's price analysis, check to measure Argenx NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Argenx NV is operating at the current time. Most of Argenx NV's value examination focuses on studying past and present price action to predict the probability of Argenx NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Argenx NV's price. Additionally, you may evaluate how the addition of Argenx NV to your portfolios can decrease your overall portfolio volatility.